NEW YORK (GenomeWeb News) — The Japanese Red Cross will use Roche’s PCR-based testing devices to screen the nation’s supply of donated blood for HIV and hepatitis B and C, the company said today.
Roche said it will supply next-generation nucleic acid-screening products to accommodate Japan’s 5 million annual blood donations. The tools will comprise Roche’s Cobas 401 and its TaqScreen MPX test, which can detect HIV-1, HIV-2, and hepatitis B and C viruses.
The company said in 2008 the 401 and the TaqScreen MPX will replace its AmpliNAT multiplex test, which has been in "routine use” in three Japanese Red Cross testing centers since 1999.
Financial terms of the agreement were not released.